Switch theme
Sign up to access all valuation multiples
Qingdao Haier Biomedical Co Ltd is engaged in designing, manufacturing, marketing and sales of low temperature storage equipment for biomedical samples. The company provides provides complete storage solutions for biological sample banks, blood safety, vaccine safety, medical supplies and reagent safety.
2005
n/a
LTM Revenue $337M
LTM EBITDA $70.6M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Haier Biomedical has a last 12-month revenue (LTM) of $337M and a last 12-month EBITDA of $70.6M.
In the most recent fiscal year, Haier Biomedical achieved revenue of $317M and an EBITDA of $73.0M.
Haier Biomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Haier Biomedical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $337M | XXX | $317M | XXX | XXX | XXX |
| Gross Profit | $162M | XXX | $152M | XXX | XXX | XXX |
| Gross Margin | 48% | XXX | 48% | XXX | XXX | XXX |
| EBITDA | $70.6M | XXX | $73.0M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $60.7M | XXX | $47.7M | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $55.1M | XXX | $50.9M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Haier Biomedical's stock price is CNY 31 (or $4).
Haier Biomedical has current market cap of CNY 9.9B (or $1.4B), and EV of CNY 8.2B (or $1.1B).
See Haier Biomedical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.4B | XXX | XXX | XXX | XXX | $0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Haier Biomedical has market cap of $1.4B and EV of $1.1B.
Haier Biomedical's trades at 3.6x EV/Revenue multiple, and 15.6x EV/EBITDA.
Equity research analysts estimate Haier Biomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Haier Biomedical has a P/E ratio of 25.0x.
See valuation multiples for Haier Biomedical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | 16.2x | XXX | 15.6x | XXX | XXX | XXX |
| EV/EBIT | 18.8x | XXX | 24.0x | XXX | XXX | XXX |
| EV/Gross Profit | 7.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 25.0x | XXX | 27.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 49.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHaier Biomedical's last 12 month revenue growth is 15%
Haier Biomedical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Haier Biomedical's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Haier Biomedical's rule of X is 60% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Haier Biomedical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | 39% | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Haier Biomedical acquired XXX companies to date.
Last acquisition by Haier Biomedical was XXXXXXXX, XXXXX XXXXX XXXXXX . Haier Biomedical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Haier Biomedical founded? | Haier Biomedical was founded in 2005. |
| Where is Haier Biomedical headquartered? | Haier Biomedical is headquartered in China. |
| Is Haier Biomedical publicy listed? | Yes, Haier Biomedical is a public company listed on SHG. |
| What is the stock symbol of Haier Biomedical? | Haier Biomedical trades under 688139 ticker. |
| When did Haier Biomedical go public? | Haier Biomedical went public in 2019. |
| Who are competitors of Haier Biomedical? | Similar companies to Haier Biomedical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Haier Biomedical? | Haier Biomedical's current market cap is $1.4B |
| What is the current revenue of Haier Biomedical? | Haier Biomedical's last 12 months revenue is $337M. |
| What is the current revenue growth of Haier Biomedical? | Haier Biomedical revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Haier Biomedical? | Current revenue multiple of Haier Biomedical is 3.4x. |
| Is Haier Biomedical profitable? | Yes, Haier Biomedical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Haier Biomedical? | Haier Biomedical's last 12 months EBITDA is $70.6M. |
| What is Haier Biomedical's EBITDA margin? | Haier Biomedical's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Haier Biomedical? | Current EBITDA multiple of Haier Biomedical is 16.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
